CD8A and neoplasm: Recent discovery on the critical role of cDC1s (type 1 conventional DCs) in cross-priming tumor antigen-specific CD8 T cells and in determining the efficacy of cancer immunotherapies [21,22,23,24,25], further highlighted the importance of the development and refinement of DC-based vaccines either as monotherapy or combinational immunotherapies.